Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Next Previous
X
Search
Trial Profile

Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Colesevelam (Primary) ; Rosiglitazone (Primary) ; Sitagliptin (Primary)
  • Indications Hyperlipidaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 15 May 2009 Results were presented in a DaiichiSankyo media release, and at the 18th Annual Meeting of the American Association of Clinical Endocrinologists.
    • 10 Apr 2009 Status changed from active, no longer recruiting to completed as reported by clintrial.gov.
    • 24 Mar 2008 Status changed from recruiting to in progress on clinicaltrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top